
Tarek Assi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5066925/publications.pdf Version: 2024-02-01



Τλρεκ Δοςι

#	Article	IF	CITATIONS
1	The Therapeutic use of human albumin in cancer patients' management. Critical Reviews in Oncology/Hematology, 2017, 120, 203-209.	2.0	48
2	Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?. Immunotherapy, 2020, 12, 351-354.	1.0	42
3	Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. British Journal of Cancer, 2020, 122, 1124-1132.	2.9	41
4	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Critical Reviews in Oncology/Hematology, 2020, 153, 103029.	2.0	35
5	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
6	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World Journal of Gastroenterology, 2016, 22, 10124.	1.4	27
7	A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. Cancer Treatment Reviews, 2019, 72, 37-44.	3.4	27
8	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer, 2020, 126, 98-104.	2.0	25
9	Targeting the VEGF Pathway in Osteosarcoma. Cells, 2021, 10, 1240.	1.8	24
10	Abridged geriatric assessment is a better predictor of overall survival than the Karnofsky Performance Scale and Physical Performance Test in elderly patients with cancer. Journal of Geriatric Oncology, 2017, 8, 128-132.	0.5	23
11	A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. Critical Reviews in Oncology/Hematology, 2020, 147, 102889.	2.0	23
12	Treatment of cancer patients in their last month of life: aimless chemotherapy. Supportive Care in Cancer, 2016, 24, 1603-1608.	1.0	22
13	Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence. EJNMMI Research, 2019, 9, 78.	1.1	21
14	Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy, 2017, 9, 309-311.	1.0	20
15	A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. Critical Reviews in Oncology/Hematology, 2018, 130, 60-69.	2.0	20
16	Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis. Sarcoma, 2020, 2020, 1-6.	0.7	20
17	Second-line Treatments of Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2019, 53, 251-261.	1.1	19
18	Do immune checkpoint inhibitors perform identically in patients with weight extremes?. Immunotherapy, 2018, 10, 733-736.	1.0	17

#	Article	IF	CITATIONS
19	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. Oncology Research and Treatment, 2020, 43, 299-306.	0.8	17
20	Viral-induced Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 438-442.	0.2	16
21	What the oncologist needs to know about COVID-19 infection in cancer patients. Future Oncology, 2020, 16, 1153-1156.	1.1	15
22	A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. Immunotherapy, 2018, 10, 657-663.	1.0	14
23	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. Immunotherapy, 2019, 11, 913-920.	1.0	13
24	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. Immunotherapy, 2017, 9, 451-460.	1.0	12
25	A Predictive Clinical-Radiomics Nomogram for Survival Prediction of Glioblastoma Using MRI. Diagnostics, 2021, 11, 2043.	1.3	12
26	Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Investigational New Drugs, 2016, 34, 474-480.	1.2	11
27	Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient. Anti-Cancer Drugs, 2020, 31, 85-89.	0.7	11
28	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Future Oncology, 2019, 15, 909-923.	1.1	10
29	Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e26-e28.	0.7	9
30	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. Immunotherapy, 2019, 11, 591-598.	1.0	9
31	Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists. Bulletin Du Cancer, 2019, 106, 590-603.	0.6	9
32	Screening Strategies for COVID-19 in Patients With Hematologic Malignancies. Frontiers in Oncology, 2020, 10, 1267.	1.3	9
33	TRK inhibition in soft tissue sarcomas: A comprehensive review. Seminars in Oncology, 2020, 47, 73-84.	0.8	9
34	Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. Journal of Gastrointestinal Cancer, 2018, 49, 21-24.	0.6	8
35	The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. Immunotherapy, 2018, 10, 1047-1052.	1.0	8
36	Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. Clinical and Translational Oncology, 2019, 21, 1135-1141.	1.2	8

#	Article	IF	CITATIONS
37	Chemotherapy in the management of periosteal osteosarcoma: A narrative review. Journal of Bone Oncology, 2021, 30, 100389.	1.0	8
38	Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss?. Quality of Life Research, 2016, 25, 1597-1604.	1.5	7
39	PDL-1/PD1 inhibitors: antibody or antinobody?. Future Oncology, 2017, 13, 1669-1671.	1.1	7
40	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. Annals of Translational Medicine, 2020, 8, 1709-1709.	0.7	7
41	The role of palliative care in the last month of life in elderly cancer patients. Supportive Care in Cancer, 2017, 25, 599-605.	1.0	6
42	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. Clinical and Translational Oncology, 2019, 21, 280-288.	1.2	6
43	Factors associated with the time to first palliative care consultation in Lebanese cancer patients. Supportive Care in Cancer, 2019, 27, 1529-1533.	1.0	6
44	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. Future Oncology, 2020, 16, 1455-1461.	1.1	6
45	Distribution of Testicular Tumors in Lebanon: A Single Institution Overview. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3443-3446.	0.5	6
46	Isolated Celiac and Splenic Artery Dissection: A Case Report and Review of the Literature. Case Reports in Vascular Medicine, 2015, 2015, 1-3.	0.1	5
47	The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?. Future Oncology, 2017, 13, 2785-2790.	1.1	5
48	Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?. Future Oncology, 2018, 14, 891-895.	1.1	5
49	Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. Diagnostics, 2021, 11, 1263.	1.3	5
50	Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine. Future Oncology, 2016, 12, 2359-2361.	1.1	4
51	ls minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?. Future Oncology, 2017, 13, 381-383.	1.1	4
52	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. International Journal of Hematologic Oncology, 2017, 6, 105-111.	0.7	4
53	Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula?. Internal Medicine Journal, 2018, 48, 1382-1388.	0.5	4
54	Geriatric cancer trends in the Middle-East: Findings from Lebanese cancer projections until 2025. Journal of Geriatric Oncology, 2018, 9, 120-123.	0.5	4

#	Article	lF	CITATIONS
55	Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries. World Journal of Clinical Cases, 2020, 8, 487-503.	0.3	4
56	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. Anti-Cancer Drugs, 2019, 30, 1052-1054.	0.7	3
57	Overview on the role of preoperative therapy in the management of kidney cancer. Clinical and Translational Oncology, 2020, 22, 11-20.	1.2	3
58	Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country. Journal of Cancer Research and Therapeutics, 2018, 14, 1112-1116.	0.3	3
59	Characteristics of Incident Testicular Cancer in Lebanon - 1990-2015 Single Institutional Experience. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1899-1902.	0.5	3
60	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. International Journal of Clinical and Experimental Pathology, 2015, 8, 3294-8.	0.5	3
61	Epidemiology and Survival Analysis of Gastrointestinal Stromal Tumors in Lebanon: Real-life study from a Hospital tumor registry 2000-2015. gulf journal of oncology, The, 2017, 1, 38-42.	0.2	3
62	Pancreatic small cell cancer. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 276-280.	0.7	2
63	An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents. Bulletin Du Cancer, 2017, 104, 385-387.	0.6	2
64	Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care, 2018, 13, 119-123.	0.8	2
65	Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?. Immunotherapy, 2022, 14, 271-274.	1.0	2
66	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. European Journal of Cancer, 2022, 167, 42-53.	1.3	2
67	Solitary Laryngeal Metastasis from Transitional Cell Carcinoma of the Kidney: Clinical Case and Review of the Literature. Case Reports in Otolaryngology, 2015, 2015, 1-2.	0.1	1
68	Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole. Anti-Cancer Drugs, 2017, 28, 931-933.	0.7	1
69	Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients. Annals of Oncology, 2018, 29, viii589.	0.6	1
70	Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?. Future Oncology, 2019, 15, 3185-3187.	1.1	1
71	Should we screen patients with hematologic malignancies for <scp>COVID</scp> â€19?. Hematological Oncology, 2020, 38, 648-653.	0.8	1
72	Epithelioid sarcoma as the prototype for personalized therapy in soft tissue sarcoma. Personalized Medicine, 2020, 17, 241-244.	0.8	1

#	Article	IF	CITATIONS
73	Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?. Immunotherapy, 2021, 13, 91-93.	1.0	1
74	COVIDâ€19 pandemic shakes the trust between oncologists and their patients. International Journal of Clinical Practice, 2021, 75, e14556.	0.8	1
75	Immune checkpoints inhibitors in metastatic squamous cell carcinoma of the vulva. Future Oncology, 2021, 17, 3133-3135.	1.1	1
76	Long-term extracranial metastatic relapse of an intraventricular solitary fibrous tumor. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	1
77	Is there a role for immune checkpoint inhibitors in chordoma?. Immunotherapy, 2021, 13, 967-970.	1.0	1
78	Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT. Blood, 2018, 132, 4226-4226.	0.6	1
79	Life threatening bleeding from an osteonecrosis of the jaw: Are bisphosphonates safe in irradiated head and neck cancer patients?. gulf journal of oncology, The, 2018, 1, 72-74.	0.2	1
80	Sarcoma of unknown primary: myth or reality?. Journal of the Egyptian National Cancer Institute, 2022, 34, .	0.6	1
81	Venous Thrombosis Associated with Peripherally Inserted Central Catheters in Oncology Patients: A Single Institutional Experience. Journal of Palliative Care & Medicine, 2014, 05, .	0.1	0
82	Efficacy of a Silicon Based Continuous Scalp Cooling System with Thermostat on Chemotherapy Induced Alopecia. Journal of Palliative Care & Medicine, 2015, 05, .	0.1	0
83	The Forgotten Complication of Recurrent Nephrolithiasis: "Squamous Cell Carcinoma of the Renal Pelvisâ€â€"A Case and Review of the Literature. Case Reports in Urology, 2015, 2015, 1-4.	0.1	0
84	Follicular lymphoma infiltrating the skin. BMJ, The, 2015, , h5449.	3.0	0
85	Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab. Blood Coagulation and Fibrinolysis, 2016, 27, 822-824.	0.5	0
86	MP166EVALUATION OF CHRONIC KIDNEY DISEASE IN CANCER PATIENTS: IS THERE STILL A ROLE FOR THE COCKROFT-GAULT ESTIMATION. Nephrology Dialysis Transplantation, 2017, 32, iii489-iii490.	0.4	0
87	The experience of onco-palliative care multidisciplinary meetings in Hotel Dieu de France University Hospital, an ESMO designated center of integrated oncology and palliative care. Annals of Oncology, 2018, 29, viii552.	0.6	0
88	A network meta-analysis of the frontline immune-checkpoint inhibitor-based regimens in advanced non-small cell lung cancer. Annals of Oncology, 2018, 29, x22.	0.6	0
89	"Hey Mom, Now I'm Officially an Oncologist― Oncologist, 2018, 23, 1116-1117.	1.9	0
90	ls there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?. Future Oncology, 2019, 15, 3877-3879.	1.1	0

#	Article	IF	CITATIONS
91	Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon. Journal of Geriatric Oncology, 2019, 10, 365-367.	0.5	0
92	Detection of PIK3R1 (L449S) Mutation in a Patient with Ovarian Cancer: A Case Report. Case Reports in Oncology, 2020, 13, 188-192.	0.3	0
93	Inflammatory Breast Cancer : A Race against Screening. Journal Medical Libanais, 2017, 65, 52-54.	0.0	0
94	A Two-Front War : Targeting Synchronous Metastatic Pancreatic and Renal Cell Carcinomas with the Combination of Gemcitabine and Sunitinib. Journal Medical Libanais, 2017, 65, 234-236.	0.0	0
95	Upfront isolated limb perfusion (ILP) in untreated patients with unresectable non-metastatic primary soft-tissue sarcomas (STS) of the limb: The Gustave Roussy experience Journal of Clinical Oncology, 2018, 36, 11569-11569.	0.8	0
96	Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 2001-2001.	0.6	0
97	Unusual Destruction of the Nasal Septum. gulf journal of oncology, The, 2016, 1, 61-63.	0.2	0
98	Total Parenteral Nutrition in Middle Eastern Cancer Patients at End of Life: Is it Justified?. gulf journal of oncology, The, 2019, 1, 21-25.	0.2	0
99	Current Status of Cancer-Related Pain and Opioid use in South Lebanon: A Pilot Study. gulf journal of oncology, The, 2020, 1, 52-57.	0.2	ο